A Phase Ⅱ Clinical Study of Combination Therapy of SKB264 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Study Details
Study Description
Brief Summary
The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: SKB264+KL-A167 Participants received SKB264 followed by KL-A167 |
Drug: SKB264
SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
Drug: KL-A167
KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
|
| Experimental: SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type) Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin |
Drug: SKB264
SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
Drug: KL-A167
KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
Drug: Carboplatin
Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
Drug: Cisplatin
Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
|
| Experimental: SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation) Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin |
Drug: SKB264
SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
Drug: KL-A167
KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
Drug: Carboplatin
Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
Drug: Cisplatin
Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
|
Outcome Measures
Primary Outcome Measures
- Incidence and severity of adverse events (AEs) [From signature completion of ICF to 30 days after the last dose or to the beginning of the new anti-cancer therapy, up to 24 months]
Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
- Objective Response Rate (ORR) [From the date of the first dose until disease progression or death (whichever occurs first), up to 24 months]
Objective Response Rate (ORR) is defined as the proportion of participants who achieved a best overall response (BOR) of complete response (CR) or partial response (PR), evaluated based on RECIST v1.1 criteria
Secondary Outcome Measures
- Progression-free survival (PFS) [From the date of the first dose until disease progression or death (whichever occurs first), up to 24 months]
- Duration of response (DOR) [From first objective response ( CR or PR) to PD or death (whichever occurs first), up to 24 months]
- Disease control rate (DCR) [From the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, up to 24 months]
- Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of SKB264-ADC, SKB264-TAB and free KL610023 [Cycle 1-8, every 4 cycles starting from Cycle 12 Day 1: pre-dose, post-dose (each cycle is 21 days), up to 24 months]
- Pharmacokinetic Parameter Minimum Plasma Concentration (Cmin) of SKB264-ADC, SKB264-TAB and free KL610023 [Cycle 1-8, every 4 cycles starting from Cycle 12 Day 1: pre-dose, post-dose (each cycle is 21 days), up to 24 months]
- Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of KL-A167 [Cycle 1-8, every 4 cycles starting from Cycle 12 Day 1: pre-dose, post-dose (each cycle is 21 days), up to 24 months]
- Pharmacokinetic Parameter Minimum Plasma Concentration (Cmin) of KL-A167 [Cycle 1-8, every 4 cycles starting from Cycle 12 Day 1: pre-dose, post-dose (each cycle is 21 days), up to 24 months]
- Anti-drug Antibodies (ADA) for SKB264 and KL-A167 [Cycle 1-8, every 4 cycles starting from Cycle 12 Day 1: pre-dose, post-dose (each cycle is 21 days), up to 24 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Males or females ≥ 18 and ≤ 75 years of age at the time of signing the informed consent form;
-
Histologically and cytologically confirmed NSCLC;
-
Cohort 1: Patients with locally advanced/metastatic NSCLC with wild-type EGFR and negative ALK fusion gene, no or at most one prior line of systemic chemotherapy regimen for advanced or metastatic NSCLC. Cohort 2: Patients with locally advanced/metastatic NSCLC with wild-type EGFR and negative ALK fusion gene, no prior systemic therapy. Cohort 3: Patients with locally advanced/metastatic NSCLC with EGFR activating mutation and negative ALK fusion gene, who have failed previous treatment with EGFR-TKIs.
-
Provide fresh or archival tumor tissue for biomarker testing and analysis;
-
Patients with at least one measurable lesion per RECIST v1.1 criteria, and patients with only skin or bone lesions cannot be enrolled;
-
Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with an expected survival of ≥ 12 weeks;
-
Adequate organ and bone marrow function
-
For female patients of childbearing age and male patients with partners of childbearing age, they must use effective medical contraception during the study treatment period and for 6 months after the last dose of study medication (see Annex for specific contraceptive measures);
-
Each patient must voluntarily agree to participate in the study, sign the informed consent form, and comply with the protocol-specified visits and relevant procedures.
Exclusion Criteria:
-
Presence of small cell lung carcinoma (SCLC) components in histological pathology;
-
History of other malignancies;
-
Presence of metastases to brainstem, meninges and spinal cord, or spinal cord compression;
-
Presence of active central nervous system (CNS) metastases;
-
Imaging (CT or MRI) shows that the tumor surrounds important blood vessels, or the investigator determines that the tumor is most likely to invade important blood vessels during the subsequent study to cause fatal major hemorrhage;
-
Serious or uncontrolled cardiac disease or clinical symptoms requiring treatment, including any of the following:
-
Patients with (noninfectious) interstitial lung disease (ILD) or history of pneumonia requiring steroid therapy; patients with serious pulmonary function impairment due to lung disease;
-
Uncontrolled systemic disease as judged by the investigator, included uncontrolled hypertension, uncontrolled diabetes, pesence of pleural effusion, pericardial effusion, or ascites that is clinically symptomatic or requires repeated drainage;
-
Certain viral infections including active hepatitis B or hepatitis C; known history of positive human immunodeficiency virus (HIV) test or known acquired immunodeficiency syndrome (AIDS); or positive syphilis antibody test;
-
Known active tuberculosis;
-
Known hypersensitivity to the study drug or any of its components, or severe allergic reactions to other monoclonal antibodies;
-
Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
-
Pregnant or lactating women;
-
Any patient whose condition deteriorates rapidly during the screening process prior to the first dose, such as severe changes in performance status, unstable pain requiring adjustment of analgesic therapy, etc
-
Other circumstances that, in the opinion of the investigator, are not appropriate for participation in this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong | China | 510060 |
Sponsors and Collaborators
- Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SKB264-Ⅱ-05